Acolbifene

Research use only, not for human use.

Acolbifene is a selective antagonist of estrogen receptors with IC50s of 2 nM and 0.4 nM for estradiol-induced transcriptional activity of ERα and ERβ. Acolbifene shows an anticarcinogenic property.

Acolbifene is a selective antagonist of estrogen receptors with IC50s of 2 nM and 0.4 nM for estradiol-induced transcriptional activity of ERα and ERβ. Acolbifene shows an anticarcinogenic property.(In Vitro):Acolbifene supports the involvement of the clearance-related receptors in its hypocholesterolemic action without affecting pathways of cholesterol synthesis. Acolbifene inhibits estradiol-stimulated cell proliferation in human breast cancer cancer cells including ZR-75-1, MCF-7 and T-47D.(In Vivo):In female Sprague-Dawley rats, Acolbifene (2.5 mg/kg; gavage) reduces food intake, strongly decreases cholesterolemia and prevents tumor growth. Acolbifene reduces food intake (16%) and weight gain (45%, mainly fat).

EM-652

Endocrinology/Hormones

Estrogen Receptor/ERR

——

——

——

182167-02-8

457.6

C29H31NO4

>98% (HPLC)

——

CC1=C([C@@H](OC=2C1=CC=C(O)C2)C3=CC=C(OCCN4CCCCC4)C=C3)C5=CC=C(O)C=C5

——

(-20℃)

With Ice Pack

≥ 2 years